Eli Lilly Sues Actavis to Halt Generic Axiron ANDA

Generic Line
Eli Lilly and Acrux on Nov. 12 filed suit against Actavis to prevent the generic drugmaker from commercializing a generic version of the testosterone topical solution Axiron.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00